Noreen Roth Henig's Insider Trades & SAST Disclosures
Noreen Roth Henig's most recent trade in Avidity Biosciences Inc was a trade of 13,489 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 13, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Noreen Roth Henig.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,489 | 13,489 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 280,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges